ALGS icon

Aligos Therapeutics

39.84 USD
+1.49
3.89%
At close Dec 20, 4:00 PM EST
After hours
40.34
+0.50
1.26%
1 day
3.89%
5 days
16.90%
1 month
118.90%
3 months
335.89%
6 months
283.08%
Year to date
124.58%
1 year
161.25%
5 years
-89.27%
10 years
-89.27%
 

About: Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Employees: 68

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

7.93% less ownership

Funds ownership: 63.04% [Q2] → 55.11% (-7.93%) [Q3]

11% less capital invested

Capital invested by funds: $16.6M [Q2] → $14.7M (-$1.9M) [Q3]

45% less funds holding

Funds holding: 49 [Q2] → 27 (-22) [Q3]

88% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 25

96% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 23

100% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 0 (-2) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$75
88%
upside
Avg. target
$75
88%
upside
High target
$75
88%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Ed Arce
54% 1-year accuracy
79 / 146 met price target
88%upside
$75
Buy
Reiterated
7 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 5,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on December 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 month ago
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA.
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Negative
Zacks Investment Research
1 month ago
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to loss of $10.25 per share a year ago.
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024.
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Neutral
GlobeNewsWire
2 months ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 95,000 shares of the Company's stock (the “Inducement Grants”) to newly hired employees on October 8, 2024 (the “Grant Date”), in connection with the commencement of employment. Included in the aggregate number is the grant of an option to purchase 75,000 shares to Dr. Hardean Achneck, in connection with the commencement of his role as Chief Medical Officer.
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
2 months ago
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately.
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
Neutral
GlobeNewsWire
2 months ago
Aligos Therapeutics to Present at Investor Conferences in October
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will participate at two investor conferences being webcast in October:
Aligos Therapeutics to Present at Investor Conferences in October
Neutral
GlobeNewsWire
3 months ago
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects.
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
Neutral
GlobeNewsWire
3 months ago
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT.
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
Neutral
GlobeNewsWire
3 months ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 3,500 shares of the Company's stock (the “Inducement Grant”) to a newly hired employee on September 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Charts implemented using Lightweight Charts™